Aquestive Therapeutics, Inc. (AQST) Operating cash flow 2017–2025
Aquestive Therapeutics, Inc. (AQST) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$52.4MFY2025 · since FY2017: $5.8M → -$52.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$52.4M | -46.6% |
| FY2024 | -$35.8M | -460.5% |
| FY2023 | -$6.4M | +35.0% |
| FY2022 | -$9.8M | +70.2% |
| FY2021 | -$33.0M | +27.5% |
| FY2020 | -$45.5M | +24.5% |
| FY2019 | -$60.2M | -363.5% |
| FY2018 | -$13.0M | -323.1% |
| FY2017 | $5.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More AQST financial trends
AQST RevenueAQST Net incomeAQST Net marginAQST Gross profitAQST Gross marginAQST Operating incomeAQST Operating marginAQST Free cash flowAQST Capital expendituresAQST Return on equityAQST Stock buybacksAQST Dividends paidAQST Total assetsAQST Total liabilitiesAQST Shareholders’ equityAQST overview →